Antibody-drug conjugates targeting TROP-2 and incorporating SN-38: A case study of anti-TROP-2 sacituzumab govitecan

References

• Sievers EL, Senter PD. Antibody-drug conjugates in cancer therapy. Annu Rev Med. 2013;64:15–29. doi:10.1146/annurev-med-050311-201823.
   PubMed Web of Science ®Google Scholar
• Leal M, Sapra P, Hurvitz SA, Senter P, Wahl A, Schutten M, Shah, D.K., Haddish‐Berhane, N. and Kabbarah, O. Antibody-drug conjugates: an emerging modality for the treatment of cancer. Ann N Y Acad Sci. 2014;1321:41–54. doi:10.1111/nyas.12499.
   PubMed Web of Science ®Google Scholar
• Govindan SV, Sharkey RM, Goldenberg DM. Prospects and progress of antibody-drug conjugates in solid tumor therapies. Expert Opin Biol Ther. 2016;16:883–93. doi:10.1517/14712598.2016.1173203.
   PubMed Web of Science ®Google Scholar
• Abdollahpour-Alitappeh M, Lotfinia M, Gharibi T, Mardaneh J, Farhadihosseinabadi B, Larki P, Faghfourian B, Sepehr KS, Abbaszadeh-Goudarzi K, Abbaszadeh-Goudarzi G, et al. Antibody-drug conjugates (ADCs) for cancer therapy: strategies, challenges, and successes. J Cell Physiol. 2019;234:5628–42. doi:10.1002/jcp.27419.
   PubMed Web of Science ®Google Scholar
• Birrer MJ, Moore KN, Betella I, Bates RC. in press. Antibody-drug conjugate-based therapeutics: state of the Science. J Natl Cancer Inst. 2019 Mar 11. pii: djz035. doi:10.1093/jnci/djz035. [Epub ahead of print]
   Google Scholar
• Ricart AD. Antibody-drug conjugates of calicheamicin derivative: gemtuzumab ozogamicin and inotuzumab ozogamicin. Clin Cancer Res. 2011;17:6417–27.
   PubMed Web of Science ®Google Scholar
• Alley SC, Okeley NM, Senter PD. Antibody-drug conjugates: targeted drug delivery for cancer. Curr Opin Chem Biol. 2010;14:529–37.
   PubMed Web of Science ®Google Scholar
• Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, Pegram, M, Oh, DY, Diéras, V and Guardino, E, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367:1783–91.
   PubMed Web of Science ®Google Scholar
• Moore KN, Vergote I, Oaknin A, Colombo N, Banerjee S, Oza A, Pautier, P, Malek, K and Birrer, MJ. FORWARD I: A Phase III study of mirvetuximab soravtansine versus chemotherapy in platinum-resistant ovarian cancer. Future Oncol. 2018;14:1669–78.
   PubMed Web of Science ®Google Scholar
• Hamblett KJ, Senter PD, Chace DF, Sun MM, Lenox J, Cerveny CG, Kissler, KM, Bernhardt, SX, Kopcha, AK, Zabinski, RF, et al. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin Cancer Res. 2004;10:7063–70. doi:10.1158/1078-0432.CCR-04-0789.
   PubMed Web of Science ®Google Scholar
• Strop P, Delaria K, Foletti D, Witt JM, Hasa-Moreno A, Poulsen K, Casas, MG, Dorywalska, M, Farias, S, Pios, A, et al. Site-specific conjugation improves therapeutic index of antibody drug conjugates with high drug loading. Nat Biotechnol. 2015;33:694–96.
   PubMed Web of Science ®Google Scholar
• Carter PJ, Senter PD. Antibody-drug conjugates for cancer therapy. Cancer J. 2008;14:154–69. doi:10.1097/PPO.0b013e318172d704.
   PubMed Web of Science ®Google Scholar
• Goldenberg DM, Cardillo TM, Govindan SV, Rossi EA, Sharkey RM. Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC). Oncotarget. 2015;6:22496–512. doi:10.18632/oncotarget.4318.
   PubMed Web of Science ®Google Scholar
• Goldenberg DM, Stein R, Sharkey RM. The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target. Oncotarget. 2018;9:28989–9006. doi:10.18632/oncotarget.25615.
   PubMedGoogle Scholar
• Lipinski M, Parks DR, Rouse RV, Herzenberg LA. Human trophoblast cell-surface antigens defined by monoclonal antibodies. Proc Natl Acad Sci USA. 1981;78:5147–50. doi:10.1073/pnas.78.8.5147.
   PubMed Web of Science ®Google Scholar
• Cubas R, Li M, Chen C, Yao Q. Trop2: A possible therapeutic target for late stage epithelial carcinomas. Biochim Biophys Acta. 2009;1796:309–14. doi:10.1016/j.bbcan.2009.08.001.
   PubMed Web of Science ®Google Scholar
• Shvartsur A, Bonavida B. Trop2 and its overexpression in cancers: regulation and clinical/therapeutic implications. Genes Cancer. 2015;6:84–105. doi:10.18632/genesandcancer.40.
   PubMedGoogle Scholar
• Stein R, Basu A, Chen S, Shih LB, Goldenberg DM. Specificity and properties of MAb RS7-3G11 and the antigen defined by this pancarcinoma monoclonal antibody. Int J Cancer. 1993;55:938–46.
   PubMed Web of Science ®Google Scholar
• Basu A, Goldenberg DM, Stein R. The epithelial/carcinoma antigen EGP-1, recognized by monoclonal antibody RS7-3G11, is phosphorylated on serine 303. Int J Cancer. 1995;62:472–79.
   PubMed Web of Science ®Google Scholar
• Stein R, Basu A, Goldenberg DM, Lloyd KO, Mattes MJ. Characterization of cluster 13: the epithelial/carcinoma antigen recognized by MAb RS7. Int J Cancer Suppl. 1994;8:98–102.
   PubMedGoogle Scholar
• De Leij L, Helrich W, Stein R, Mattes MJ. SCLC-cluster-2 antibodies detect the pancarcinoma/epithelial glycoprotein EGP-2. Int J Cancer Suppl. 1994;8:60–63.
   PubMedGoogle Scholar
• Shih LB, Xuan H, Aninipot R, Stein R, Goldenberg DM. In vitro and in vivo reactivity of an internalizing antibody, RS7, with human breast cancer. Cancer Res. 1995;55:5857s–63s.
   PubMed Web of Science ®Google Scholar
• Cardillo TM, Govindan SV, Sharkey RM, Trisal P, Arrojo R, Liu D, Rossi EA, Chang C-H, Goldenberg DM. Sacituzumab govitecan (IMMU-132), an anti-Trop-2/SN-38 antibody-drug conjugate: characterization and efficacy in pancreatic, gastric, and other cancers. Bioconjug Chem. 2015;26:919–31. doi:10.1021/acs.bioconjchem.5b00223.
   PubMed Web of Science ®Google Scholar
• Mathijssen RH, van Alphen RJ, Verweij J, Loos WJ, Nooter K, Stoter G, Sparreboom A. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res. 2001;7:2182–94.
   PubMed Web of Science ®Google Scholar
• Garcia-Carbonero R, Supko JG. Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins. Clin Cancer Res. 2002;8:641–61.
   PubMed Web of Science ®Google Scholar
• Moon SJ, Govindan SV, Cardillo TM, D’Souza CA, Hansen HJ, Goldenberg DM. Antibody conjugates of 7-ethyl-10-hydroxycamptothecin (SN-38) for targeted cancer chemotherapy. J Med Chem. 2008;51:6916–26. doi:10.1021/jm800719t.
   PubMed Web of Science ®Google Scholar
• Govindan SV, Cardillo TM, Moon SJ, Hansen HJ, Goldenberg DM. CEACAM5-targeted therapy of human colonic and pancreatic cancer xenografts with potent labetuzumab-SN-38 immunoconjugates. Clin Cancer Res. 2009;15:6052–61. doi:10.1158/1078-0432.CCR-09-0586.
   PubMed Web of Science ®Google Scholar
• Govindan SV, Cardillo TM, Goldenberg DM. Chapter 8: topoisomerase inhibitors as antibody-drug conjugate payloads. In: Thurston DE, Jackson PJM, editors. Cytotoxic payloads for antibody-drug conjugates. Cambridge (UK): Royal Society of Chemistry; 2019. p. 164–84.
   Google Scholar
• Cardillo TM, Govindan SV, Sharkey RM, Trisal P, Goldenberg DM. Humanized anti-Trop-2 IgG-SN-38 conjugate for effective treatment of diverse epithelial cancers: preclinical studies in human cancer xenograft models and monkeys. Clin Cancer Res. 2011;17:3157–69. doi:10.1158/1078-0432.CCR-10-2939.
   PubMed Web of Science ®Google Scholar
• Sharkey RM, McBride WJ, Cardillo TM, Govindan SV, Wang Y, Rossi EA, Chang C-H, Goldenberg DM. Enhanced delivery of SN-38 to human tumor xenografts with an anti-Trop-2-SN-38 antibody conjugate (sacituzumab govitecan). Clin Cancer Res. 2015;21:5131–38. doi:10.1158/1078-0432.CCR-15-0670.
   PubMed Web of Science ®Google Scholar
• Bignotti E, Ravaggi A, Romani C, Falchetti M, Lonardi S, Facchetti F, Pecorelli S, Varughese J, Cocco E, Bellone S, et al. Trop-2 overexpression in poorly differentiated endometrial endometrioid carcinoma: implications for immunotherapy with hRS7, a humanized anti-trop-2 monoclonal antibody. Int J Gynecol Cancer. 2011;21:1613–21. doi:10.1097/IGC.0b013e318228f6da.
   PubMed Web of Science ®Google Scholar
• Raji R, Guzzo F, Carrara L, Varughese J, Cocco E, Bellone S, Betti, M, Todeschini, P, Gasparrini, S, Ratner, E, et al. Uterine and ovarian carcinosarcomas overexpressing Trop-2 are sensitive to hRS7, a humanized anti-Trop-2 antibody. J Exp Clin Cancer Res. 2011;30:106. doi:10.1186/1756-9966-30-24.
   PubMed Web of Science ®Google Scholar
• Varughese J, Cocco E, Bellone S, Ratner E, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Buza N, Pecorelli S, et al. Cervical carcinomas overexpress human trophoblast cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized monoclonal anti-Trop-2 antibody. Am J Obstet Gynecol. 2011;205:567.e1-7. doi:10.1016/j.ajog.2011.06.093.
   PubMed Web of Science ®Google Scholar
• Lin H, Zhang H, Wang J, Lu M, Zheng F, Wang C, Tang X, Xu N, Chen R, Zhang D, et al. A novel human Fab antibody for Trop2 inhibits breast cancer growth in vitro and in vivo. Int J Cancer. 2014;134:1239–49. doi:10.1002/ijc.28451.
   PubMed Web of Science ®Google Scholar
• Liu J, Yang D, Yin Z, Gao M, Tong H, Su Y, Zhu, J, Ye, C and Zhang, H, et al. A novel human monoclonal Trop2-IgG antibody inhibits ovarian cancer growth in vitro and in vivo. Biochem Biophys Res Commun. 2019 Apr 30;512(2):276–282. doi:10.1016/j.bbrc.2019.03.028. Epub 2019 Mar 14.
   Google Scholar
• Mao Y, Wang X, Zheng F, Wang C, Tang Q, Tang X, Xu N, Zhang H, Zhang D, Xiong L, et al. The tumor-inhibitory effectiveness of a novel anti-Trop2 Fab conjugate in pancreatic cancer. Oncotarget. 2016;7:24810–23. doi:10.18632/oncotarget.8529.
   PubMedGoogle Scholar
• Cardillo TM, Mostafa AA, Rossi DL, Liu D, Chang CH, Sharkey RM, and Goldenberg, DM. Treatment of high Trop-2-expressing triple-negative breast cancer (TNBC) with sacituzumab govitecan (IMMU-132) overcomes homologous recombination repair (HRR) rescue mediated by Rad51. Cancer Res. 2017;77(abstract):3193.
   Google Scholar
• Bardia A, Mayer IA, Diamond JR, Moroose RL, Isakoff SJ, Starodub AN, Shah NC, O’Shaughnessy J, Kalinsky K, Guarino M, et al. Efficacy and safety of anti-Trop-2 antibody drug conjugate sacituzumab govitecan (IMMU-132) in heavily pretreated patients with metastatic triple-negative breast cancer. J Clin Oncol. 2017;35:2141–48. doi:10.1200/JCO.2016.70.8297.
   PubMed Web of Science ®Google Scholar
• Gray JE, Heist RS, Starodub AN, Camidge DR, Kio EA, Masters GA, Purcell WT, Guarino MJ, Misleh J, Schneider CJ, et al. Therapy of small cell lung cancer (SCLC) with a topoisomerase-I-inhibiting antibody-drug conjugate (ADC) targeting Trop-2, sacituzumab govitecan. Clin Cancer Res. 2017;23:5711–19. doi:10.1158/1078-0432.CCR-17-0933.
   PubMed Web of Science ®Google Scholar
• Heist RS, Guarino MJ, Masters G, Purcell WT, Starodub AN, Horn L, Scheff RJ, Bardia A, Messersmith WA, Berlin J, et al. Therapy of advanced non-small-cell lung cancer with an SN-38-anti-Trop-2 drug conjugate, sacituzumab govitecan. J Clin Oncol. 2017;35:2790–97. doi:10.1200/JCO.2016.72.1894.
   PubMed Web of Science ®Google Scholar
• Starodub AN, Ocean AJ, Shah MA, Guarino MJ, Picozzi VJ Jr., Vahdat LT, Thomas SS, Govindan SV, Maliakal PP, Wegener WA, et al. First-in-human trial of a novel anti-Trop-2 antibody-SN-38 conjugate, sacituzumab govitecan, for the treatment of diverse metastatic solid tumors. Clin Cancer Res. 2015;21:3870–78. doi:10.1158/1078-0432.CCR-14-3321.
   PubMed Web of Science ®Google Scholar
• Staudacher AH, Brown MP. Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required? Br J Cancer. 2017(117):.1736–42
   Google Scholar
• Morton CL, Wierdl M, Oliver L, Ma MK, Danks MK, Stewart CF, Eiseman JL, Potter PM. Activation of CPT-11 in mice: identification and analysis of a highly effective plasma esterase. Cancer Res. 2000;60:4206–10.
   PubMed Web of Science ®Google Scholar
• Xie R, Mathijssen RH, Sparreboom A, Verweij J, Karlsson MO. Clinical pharmacokinetics of irinotecan and its metabolites: a population analysis. J Clin Oncol. 2002;20:3293–301. doi:10.1200/JCO.2002.11.073.
   PubMed Web of Science ®Google Scholar
• Ocean AJ, Starodub AN, Bardia A, Vahdat LT, Isakoff SJ, Guarino M, Messersmith WA, Picozzi VJ, Mayer IA, Wegener WA, et al. Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: safety and pharmacokinetics. Cancer. 2017;123:3843–54. doi:10.1002/cncr.30789.
   PubMed Web of Science ®Google Scholar
• Stein A, Voigt W, Jordan K. Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management. Ther Adv Med Oncol. 2010;2:51–63. doi:10.1177/1758834009355164.
   PubMedGoogle Scholar
• Zhao H, Lee C, Sai P, Choe YH, Boro M, Pendri A, Guan S, Greenwald RB. 20-O-acylcamptothecin derivatives: evidence for lactone stabilization 1. J Org Chem. 2000;65:4601–06.
   PubMed Web of Science ®Google Scholar
• Sharkey RM, Govindan SV, Cardillo TM, Donnell J, Xia J, Rossi EA, Chang C-H, Goldenberg DM. Selective and concentrated accretion of SN-38 with a CEACAM5-targeting antibody-drug conjugate (ADC), labetuzumab govitecan (IMMU-130). Mol Cancer Ther. 2018;17:196–203. doi:10.1158/1535-7163.MCT-17-0442.
   PubMed Web of Science ®Google Scholar
• Xie R, Mathijssen RH, Sparreboom A, Verweij J, Karlsson MO. Clinical pharmacokinetics of irinotecan and its metabolites in relation with diarrhea. Clin Pharmacol Ther. 2002;72:265–75.
   PubMed Web of Science ®Google Scholar
• Bardia A, Mayer IA, Vahdat LT, Tolaney SM, Isakoff SJ, Diamond JR, O’Shaughnessy, J, Moroose, RL, Santin, AD, Abramson, VG, et al. Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer. N Engl J Med. 2019;380:741–51.
   PubMed Web of Science ®Google Scholar
• Bardia A, Tolaney SM, Juric D, Mayer IA, Vahdat LT, Diamond JR, Kalinsky K, O'Shaughnessy J, Moroose RL, Wahskowitz S, et al. Efficacy of sacituzumab govitecan (anti-Trop-2-SN-38 antibody-drug conjugate) for endocrine-refractory hormone-receptor positive (HR+) metastatic breast cancer (mBC). J Clin Oncol. 2018;36(Abstr):1004.
   Web of Science ®Google Scholar
• Faltas B, Goldenberg DM, Ocean AJ, Govindan SV, Wilhelm F, Sharkey RM, Hajdenberg, J, Hodes, G, Nanus, DM, Tagawa, ST. Sacituzumab govitecan, a novel antibody-drug conjugate, in patients with metastatic platinum-resistant urothelial carcinoma. Clin Genitourin Cancer. 2016;14:e75–9.
   PubMed Web of Science ®Google Scholar
• Tagawa ST, Faltas B, Lam ET, Saylor P, Bardia A, JHajdenberg J, Morgans, AK, Lim, EA, Kalinsky, K, Simpson, PS, et al. Sacituzumab govitecan (IMMU-132) in patients with previously treated metastatic urothelial cancers (mUC): results from a Phase I/II study. J Clin Oncol. 2019;37(abst):354.
   Web of Science ®Google Scholar
• Tagawa ST, Petrylak DP, Grivas P, Agarwal N, Sternberg CN, Hernandez C, Siemon-Hryczyk P, Goswami T, Loriot Y. TROPHY-U-01: A phase II open-label study of sacituzumab govitecan (IMMU-132) in patients with advanced urothelial cancer after progression on platinum-based chemotherapy and/or anti-PD-1/PD-L1 checkpoint inhibitor therapy. (suppl). J Clin Oncol. 2019;37:abstrTPS3153.
   Web of Science ®Google Scholar
• Strop P, Tran TT, Dorywalska M, Delaria K, Dushin R, Wong OK, Ho, WH, Zhou, D, Wu, A, Kraynov, E, et al. RN927C, a site-specific Trop-2 antibody-drug conjugate (ADC) with enhanced stability, is highly efficacious in preclinical solid tumor models. Mol Cancer Ther. 2016;15:2698–708.
   PubMed Web of Science ®Google Scholar
• King GT, Eaton KD, Beagle BR, Zopf CJ, Wong GY, Krupka HI, Hua, SY, Messersmith, WA and El-Khoueiry, AB. A phase 1, dose-escalation study of PF-06664178, an anti-Trop-2/Aur0101 antibody-drug conjugate in patients with advanced or metastatic solid tumors. Invest New Drugs. 2018;36:836–47.
   PubMed Web of Science ®Google Scholar
• Tang W, Huang X, Ou Z, Yan H, Gan J, Dong Q, Tan, B, Yang, Y, Guo, Y, Li, S, et al. 2019. BAT8003, a potent anti-Trop-2 antibody-drug conjugate, for the treatment of triple negative breast cancer [abstract]. Cancer Res. 79(Issue 4). (suppl; In: The Proceedings of the 2018 San Antonio Breast Cancer Symposium, 2018): Abstractnr P6-20-16
   Web of Science ®Google Scholar
• Okajima D, Yasuda S, Yokouchi Y, Fujitani T, Sakurai K, Yamaguchi J, Kitamura, M, Terauchi, T, Shibutani, T, Aida, T, et al. Preclinical efficacy studies of DS-1062a, a novel TROP2-targeting antibody-drug conjugate with a novel DNA topoisomerase I inhibitor DXd. J Clin Oncol (Suppl). 2018;36(abstract):e24206.
   Web of Science ®Google Scholar
• Ogitani Y, Aida T, Hagihara K, Yamaguchi J, Ishii C, Harada N, Soma M, Okamoto H, Oitate M, Arakawa S, et al. DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1. Clin Cancer Res. 2016;22:5097–108.
   PubMed Web of Science ®Google Scholar
• Nakada T, Sugihara K, Jikoh T, Abe Y, Agatsuma T. The latest research and development into the antibody-drug conjugate, [fam-] trastuzumab deruxtecan (DS-8201a), for HER2 cancer therapy. Chem Pharm Bull (Tokyo). 2019;67:173–85.
   PubMed Web of Science ®Google Scholar
• Sands JM, Shimizu T, Garon EB, Greenberg J, Guevara FM, Heist RS, Kobayashi, F, Noguchi, Y, Okajima, D, Tajima, N, et al. First-in-human phase 1 study of DR-1062a in patients with advanced solid tumors. J Clin Oncol (Suppl). 2019;37(abstr):9051.
   Google Scholar
• Brennan J Daiichi Sankyo presents preliminary phase 1 data for TROP2 targeting ADC DS-1062 in patients with non-small cell lung cancer at 2019. ASCO annual meeting 2019; Chicago, IL.
   Google Scholar
• Doi T, Shitara K, Naito Y, Shimomura A, Fujiwara Y, Yonemori K, Shimizu, C, Shimoi, T, Kuboki, Y, Matsubara, N, et al. Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study. Lancet Oncol. 2017;18:1512–22.
   PubMed Web of Science ®Google Scholar
• Iwata TN, Ishii C, Ishida S, Ogitani Y, Wada T, Agatsuma T. A HER2-targeting antibody-drug conjugate, trastuzumab deruxtecan (DS-8201a), enhances antitumor immunity in a mouse model. Mol Cancer Ther. 2018;17:1494–503.
   PubMed Web of Science ®Google Scholar
• Ogitani Y, Hagihara K, Oitate M, Naito H, Agatsuma T. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. Cancer Sci. 2016;107:1039–46.
   PubMed Web of Science ®Google Scholar
• Takegawa N, Nonagase Y, Yonesaka K, Sakai K, Maenishi O, Ogitani Y, Tamura, T, Nishio, K, Nakagawa, K and Tsurutani, J. DS-8201a, a new HER2-targeting antibody-drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2-positive gastric cancer T-DM1 resistance. Int J Cancer. 2017;141:1682–89.
   PubMed Web of Science ®Google Scholar
• Cardillo TM, Sharkey RM, Rossi DL, Arrojo R, Mostafa AA, Goldenberg DM. Synthetic lethality exploitation by an anti-Trop-2-SN-38 antibody-drug conjugate, IMMU-132, plus PARP inhibitors in BRCA1/2-wild-type triple-negative breast cancer. Clin Cancer Res. 2017;23:3405–15. doi:10.1158/1078-0432.CCR-16-2401.
   PubMed Web of Science ®Google Scholar